Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Amanda Golembesky

Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States

Journal of Medical Economics

Health Policy

2019

English

Related publications

Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab

Journal of Cancer Therapy

2015

English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Oncotarget

Oncology

2017

English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Neoplasma

Cancer Research

2013

English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology

English

Health Care Resource Utilization and Costs of Patients With Aspergillosis in the United States

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

2020

English

PC04.01 Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First Versus Osimertinib First)

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Amanda Golembesky

Healthcare Resource Utilization and Costs Associated With Patients Prescribed Afatinib or Erlotinib as First-Line Therapy for EGFR Mutation-Positive NSCLC in the United States

Related publications

Healthcare Resource Utilization and Associated Costs in Patients With Advanced Melanoma Receiving First-Line Ipilimumab

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Health Care Resource Utilization and Costs of Patients With Aspergillosis in the United States

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

PC04.01 Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First Versus Osimertinib First)